Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
Provided By GlobeNewswire
Last update: Sep 12, 2024
― Losmapimod failed to show an improvement in relative surface area (RSA), a measure of reachable workspace (RWS), versus placebo at week 48 ―
― Fulcrum to suspend future losmapimod development ―
Read more at globenewswire.com
